NewEdge Advisors’s Arcturus Therapeutics ARCT Stock Holding History

NewEdge Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26	Closed	-$479	–	4215
2025 Q3	$479	Hold	26	–	–	﹤0.01%	3953
2025 Q2	$338	Hold	26	–	–	﹤0.01%	3842
2025 Q1	$275	Hold	26	–	–	﹤0.01%	3775
2024 Q4	$441	Hold	26	–	–	﹤0.01%	3672
2024 Q3	$603	Hold	26	–	–	﹤0.01%	3585
2024 Q2	$633	Hold	26	–	–	﹤0.01%	3540
2024 Q1	$878	Hold	26	–	–	﹤0.01%	3522
2023 Q4	$820	Hold	26	–	–	﹤0.01%	3489
2023 Q3	$664	Hold	26	–	–	﹤0.01%	3221
2023 Q2	$746	Hold	26	–	–	﹤0.01%	3283
2023 Q1	$623	Hold	26	–	–	﹤0.01%	3218
2022 Q4	$0	Buy	+26	New	+$453	﹤0.01%	4085

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

NewEdge Advisors's ARCT Position: Q4 2025 in Review

NewEdge Advisors sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 26 shares — an estimated $479 sold.

NewEdge Advisors first reported a position in ARCT in Q4 2022 and held it in 12 quarters. The position peaked at $878 in Q1 2024. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

NewEdge Advisors reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
NewEdge Advisors sold 26 Arcturus Therapeutics shares in Q4 2025, an estimated $479.
NewEdge Advisors first reported a position in Arcturus Therapeutics in Q4 2022 and held it in 12 quarters.
NewEdge Advisors's Arcturus Therapeutics position peaked at $878 in Q1 2024.
120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.